Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAILOR-DAPT: Tailored Antiplatelet Therapy vs Clopidogrel
NCT05936606Recruiting
- Sponsor
- Yonsei University
- Start
- Aug 2023
- Primary completion
- May 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of ticagrelor, clopidogrel and aspirin in coronary artery disease (CAD) (2 arms), sponsored by Yonsei University. Primary endpoint: Net Adverse Clinical Events at 24 months. Started Aug 2023; status: recruiting.
02
Drugs
ticagrelorclopidogrelaspirin
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT05936606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05936606.